- Medimpex, the largest drugs exporter in Hungary, could be restructured into three independent companies following an extraordinary general meeting due to take place on July 26, according to MTI Econews. No other details are currently available. Shareholders at the meeting will decide whether or not to establish Medimpex Medicine Wholesale, Medimpex Office Building, and Med-West. It will also be decided if capital in the individual firms will be increased. Experts believe that the creation of smaller companies will enable Medimpex to achieve greater flexibility in its business operations.
Medimpex recorded consolidated net sales of 25.8 billion forint ($1.7 billion) and gross profit of 267 million forint in 1995, reported MTI. Three of Hungary's key pharmaceutical companies are shareholders in Medimpex. Richter Gedeon and Egis hold 41.21% stakes each in Medimpex, and Biogal has a 11.73% stake in the firm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze